Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability (2023 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Non-Current Deferred Tax Liability of $30.6 million for Q1 2026, down 4.22% year-over-year from $32.0 million in Q1 2025, and down 3.81% quarter-over-quarter from $31.8 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Non-Current Deferred Tax Liability (2023 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Non-Current Deferred Tax Liability for 4 consecutive years, with $30.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 4.22% year-over-year to $30.6 million; the TTM figure through Mar 2026 stood at $30.6 million (down 4.22% YoY), while the FY2025 annual figure was $31.8 million, down 1.51% from the prior year.
- Non-Current Deferred Tax Liability fell to $30.6 million in Q1 2026 per IOVA's latest filing, from $31.8 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $34.7 million in Q2 2025 and bottomed at $17.3 million in Q4 2023.
- Historically, Non-Current Deferred Tax Liability has averaged $28.2 million across 4 years, with a median of $31.7 million in 2025.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability jumped 86.29% — and 2026, when it dropped 4.22%.
- Iovance Biotherapeutics' Non-Current Deferred Tax Liability stood at $17.3 million in 2023, then soared by 86.29% to $32.3 million in 2024, then dropped by 1.51% to $31.8 million in 2025, then retreated by 3.81% to $30.6 million in 2026.
- Business Quant data shows IOVA's Non-Current Deferred Tax Liability at $30.6 million in Q1 2026, $31.8 million in Q4 2025, and $31.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.31 Mn |
| Jun 30, 2026 | 29.31 Mn |
| Mar 31, 2026 | 30.61 Mn |
| Mar 31, 2026 | 30.61 Mn |
| Dec 31, 2025 | 31.83 Mn |
| Dec 31, 2025 | 31.83 Mn |
| Sep 30, 2025 | 31.67 Mn |
| Sep 30, 2025 | 31.67 Mn |
| Jun 30, 2025 | 34.70 Mn |
| Jun 30, 2025 | 34.70 Mn |
| Mar 31, 2025 | 31.96 Mn |
| Mar 31, 2025 | 31.96 Mn |
| Dec 31, 2024 | 32.32 Mn |
| Dec 31, 2024 | 32.32 Mn |
| Mar 31, 2024 | 33.30 Mn |
| Mar 31, 2024 | 33.30 Mn |
| Dec 31, 2023 | 17.35 Mn |
| Dec 31, 2023 | 17.35 Mn |
| Sep 30, 2023 | 18.34 Mn |
| Sep 30, 2023 | 18.34 Mn |